Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4196 Metastatic potential and associated mortality in a Greek cοhort of 123 MEN1 patients

Introduction: Prevalence of distant stage disease and overall mortality rates vary considerably among patients with multiple endocrine neoplasia type 1 (MEN1).

Conference:

Presenting Author: Papadopoulou-Marketou N

Authors: Papadopoulou-Marketou N, Daskalakis K, Chondrogianni M, Tsoli M, Kaltsas G,

Keywords: MEN1, pancreatic neuroendocrine tumor, thymus cancer,

#3786 Overview of screening and surveillance practices for MEN1-related pancreatic neuroendocrine neoplasms in ENETS CoEs – An ENETS MEN1 Task Force Questionnaire Study

Introduction: The 2012 MEN1 Clinical Practice Guidelines were based on expert opinion with limited evidence, leaving room for interpretation and variation in practices.

Conference:

Presenting Author:

Authors: Pieterman C, Kaltsas G, Valk G, On Behalf of the Enets Men1 Task Force N,

Keywords: men1, screening, surveillance, PanNEN, ENETS CoE, Questionnaire,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,

#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?

Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Tsolakis A, Kanakis G, Grimelius G, Papaioannou D, Kaltsas G,

Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67,

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Furnace M

Authors: Furnace M, Muller G, Rundell C, Shah R, Luong T,

Keywords: G3, well-differentiated, poorly differentiated, Ki-67,